Welcome to our dedicated page for Personalis news (Ticker: PSNL), a resource for investors and traders seeking the latest updates and insights on Personalis stock.
Personalis, Inc. reports recurring developments in advanced genomics for precision oncology, with emphasis on personalized cancer testing, minimal residual disease monitoring and sequencing-based data analysis services. Company updates frequently center on the NeXT Personal ultrasensitive ctDNA assay, clinical test volume, clinical revenue, Medicare coverage for breast and lung cancer surveillance, and the shift toward commercial adoption of MRD testing.
News also covers clinical data presentations and publications in oncology settings, including breast, lung and colorectal cancer, as well as product features such as Real-Time Variant Tracker for therapy-resistance monitoring. Other recurring items include quarterly results, financial guidance, biopharma research applications and governance or management changes tied to the company’s precision oncology strategy.
Personalis, Inc. (Nasdaq: PSNL) announced an ongoing collaboration with AstraZeneca (LSE/STO/Nasdaq: AZN) to explore ultra-sensitive molecular residual disease (MRD) measurement using Personalis' NeXT Personal® assay. This partnership aims to enhance the detection of circulating tumor DNA (ctDNA) and clinically relevant mutations to guide cancer therapy. The CALLA trial will focus on locally advanced cervical cancer, assessing the roles of ctDNA and HPV detection in plasma. Personalis emphasizes the assay's high sensitivity and specificity, crucial for early and personalized patient interventions.
Personalis (NASDAQ: PSNL) has announced a major leadership change aimed at progressing its strategic objectives in cancer management. Christopher Hall is appointed as the new CEO, effective immediately, alongside Aaron Tachibana promoted to COO, and Dr. Richard Chen to EVP, R&D. This leadership shift follows Hall's previous role as President since December 2022. The company's focus will be on minimal residual disease (MRD) testing and supporting personalized cancer therapies. As they work to reduce cash burn and enhance margins, these appointments are expected to bolster Personalis's position in advanced genomics.
Personalis, Inc. (Nasdaq: PSNL) reported a fourth quarter revenue of $16.7 million and a full year revenue of $65.0 million for 2022. The company experienced a net loss of $31.1 million in Q4 and $113.3 million for the year. Notably, revenue from pharma tests and enterprise customers reached $15.8 million in Q4. The firm has announced partnerships with Moderna and ongoing collaborations for clinical trials to enhance cancer treatment monitoring. For Q1 2023, Personalis expects approximately $17.5 million in revenue with a full-year forecast between $68 million and $72 million.
Personalis, Inc. (NASDAQ: PSNL) announced it will release its fourth quarter and full year 2022 financial results on February 23, 2023. A conference call and webcast will be held on the same day at 2:00 p.m. PT to discuss these results along with recent highlights. Interested participants can register in advance to access the live call. The company focuses on advanced cancer genomics, providing insights on approximately 20,000 human genes through its Personalis NeXT Platform. The laboratory is certified and accredited for its clinical accuracy and efficiency. More updates will be available after the conclusion of the call.
Personalis, Inc. (Nasdaq: PSNL), a leader in advanced cancer genomics, will participate in two upcoming investor conferences. The first is the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 16, 2023, at The Cliff Lodge in Snowbird, UT. The second is the 43rd Annual Cowen Healthcare Conference on March 7, 2023, at 10:30 a.m. Eastern Time at the Boston Marriott Copley Place in Boston, MA. Personalis is known for its NeXT Platform, which offers comprehensive insights into the human genome, aiding in precision cancer therapies. The company's laboratory is recognized for its clinical accuracy and quality.
Personalis, Inc. (PSNL) and Moderna, Inc. (MRNA) have signed a new agreement to utilize the Personalis NeXT Platform for clinical studies involving the investigational personalized cancer vaccine, mRNA-4157/V940. This platform previously supported the Phase 2b clinical study, sequencing genomic data from patient tumor samples to identify mutations that may prompt tailored antitumor responses. Chris Hall from Personalis expressed excitement about continuing their collaboration with Moderna, emphasizing the aim to advance individualized cancer treatments.
Personalis, Inc. (NASDAQ: PSNL) reported preliminary fourth-quarter revenue of approximately $16.7 million and full-year revenue of $65.0 million for 2022, surpassing previous guidance of $63.0 to $64.0 million. Key highlights include a 42% increase in revenue from biopharma and other customers, totaling $56.6 million for the year. The U.S. Department of Veterans Affairs Million Veterans Program revenue dropped to $0.9 million in Q4, down 82% year-over-year. Cash and short-term investments amounted to $167.0 million as of December 31, 2022.
Personalis, Inc. (Nasdaq: PSNL) announced the grant of non-qualified stock options for 35,000 shares and restricted stock units (RSUs) covering 42,100 shares to three new employees between December 5, 2022, and December 16, 2022. The grant is part of the 2020 Inducement Plan, aimed at attracting new talent to the company. The options have an exercise price of $2.83 and vest over four years. This decision aligns with Nasdaq regulations and reflects Personalis' commitment to enhancing its workforce as a leader in cancer genomics.
Personalis, Inc. (NASDAQ: PSNL) announced the retirement of CEO John West, effective December 31, 2022. West, a co-founder, has led the company since its inception in 2011, focusing on advanced cancer genomics. Aaron Tachibana, currently CFO, will serve as interim CEO, and Christopher Hall will be promoted to President. The board will search for a permanent CEO. West expressed pride in the company’s accomplishments in enhancing cancer treatments and genomic profiling.
Personalis, Inc. (NASDAQ: PSNL) has announced a collaboration with UC San Francisco (UCSF) to deploy a personalized liquid biopsy-based research assay for colorectal cancer. The NeXT Personal™ assay will evaluate ctDNA signatures linked to treatment response in late-stage patients undergoing therapy with capecitabine, pembrolizumab, and bevacizumab. This partnership aims to enhance early detection of treatment response and disease recurrence, addressing the limitations of current ctDNA assays.